More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1.23B
EPS
-0.02
P/E ratio
--
Price to sales
6.93
Dividend yield
--
Beta
0.94295
Previous close
$3.37
Today's open
$3.38
Day's range
$3.34 - $3.40
52 week range
$2.28 - $3.61
show more
CEO
Michael Gorenstein
Employees
356
Headquarters
Stayner, Ontario
Exchange
NASDAQ Global Market
Shares outstanding
368412864
Issue type
Common Stock
Healthcare
Pharmaceuticals
Cronos to Host 2026 Investor Day at its Cronos GrowCo Facility in Kingsville, Ontario
Registration is now open for Cronos' first Investor Day, which will be hosted by the Cronos Leadership Team, on September 24, 2026 Registration is now open for Cronos' first Investor Day, which will be hosted by the Cronos Leadership Team, on September 24, 2026
GlobeNewsWire • Sep 15, 2026

Cronos: Invest In Cannabis With 50% Net Cash And GAAP Profitability
Cronos Group Inc. is upgraded to a Buy, driven by a best-in-class balance sheet and improved profitability. CRON boasts $827 million in cash, no debt, and strong international expansion, with adjusted gross margins reaching 46%. Profitability is supported by disciplined cost management and positive GAAP operating profit, distinguishing CRON from Canadian peers.
Seeking Alpha • Sep 15, 2026

Cronos' brand Spinach® Expands its Best-Selling Lineups of Edibles and Vapes
TORONTO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos”), an innovative global cannabis company, is expanding its lineup of edible multipacks with the SOURZ by Spinach® Blue Raspberry Lemonade Fully Blasted multipack, featuring its first live resin gummy. This month the brand will also launch new flavors in its best-selling lineup of vape cartridges, Strawberry Banana and Sweet Citrus Punch.
GlobeNewsWire • Sep 2, 2026

Are Medical Stocks Lagging Cronos Group (CRON) This Year?
Here is how Cronos Group (CRON) and Curaleaf Holdings, Inc. (CURLF) have performed compared to their sector so far this year.
Zacks Investment Research • Sep 2, 2026

The Best Way Marijuana Stock Investing Can Work For You
As the cannabis industry continues to grow worldwide, there is a strong focus on the future. Many new changes are occurring throughout the sector—many of these impact businesses, investors, and potentially the end consumer. For marijuana stock investors, the new Schedule 3 bill for cannabis is soon to take effect. This will change how businesses operate, and some will have to pivot quickly.

4 Healthcare Stocks to Safeguard Your Portfolio as Fed Plans Rate Hike
A rate hike could keep markets volatile, making BVS, CNC, AMRX and CRON healthcare stocks to consider as inflation stays elevated.
Zacks Investment Research • Aug 20, 2026

Surging Earnings Estimates Signal Upside for Cronos (CRON) Stock
Cronos Group (CRON) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Zacks Investment Research • Aug 18, 2026

Marijuana reform is emerging as a midterm elections issue on both sides of the aisle
With November's pivotal midterm elections fast approaching, cannabis reform is emerging as an issue. Two states, Massachusetts and Idaho, will vote on ballot initiatives regarding legalization, and in several others, including Kansas and Iowa, gubernatorial candidates are debating cannabis matters.
CNBC • Aug 15, 2026

Cronos: Strong Quarter, And The Outlook For The Future Is Positive Thanks To M&A
Cronos Group Inc. is rapidly expanding internationally, leveraging European legalization momentum and the CanAdelaar acquisition to become a major European cannabis player. Q2 results showed 58% YoY revenue growth to $53M, with margins benefiting from favorable sales mix and stable operating expenses. CRON maintains a robust balance sheet with nearly $800M in cash and short-term investments versus $56M in current liabilities, supporting buybacks and future M&A.
Seeking Alpha • Aug 7, 2026

Cronos Group: This Cannabis Name Isn't Reliant On U.S. Legalization Efforts
Cronos delivered a Q2 2026 earnings report that met bullish investor expectations. Strong quarterly performance reinforces the investment thesis for CRON's growth trajectory. Management execution and financial results support a positive outlook for CRON.
Seeking Alpha • Aug 7, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Cronos Group Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.